{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:42:37Z","timestamp":1790700157400,"version":"4.1.0"},"reference-count":144,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The thrombotic mechanism, being common to peripheral arterial disease (PAD), acute myocardial infarction (AMI), and stroke, is responsible for the highest number of deaths in the western world. However, while much has been done for the prevention, early diagnosis, therapy of AMI and stroke, the same cannot be said for PAD, which is a negative prognostic indicator for cardiovascular death. Acute limb ischemia (ALI) and chronic limb ischemia (CLI) are the most severe manifestations of PAD. They both are defined by the presence of PAD, rest pain, gangrene, or ulceration and we consider ALI if symptoms last less than 2 weeks and CLI if they last more than 2 weeks. The most frequent causes are certainly atherosclerotic and embolic mechanisms and, to a lesser extent, traumatic or surgical mechanisms. From a pathophysiological point of view, atherosclerotic, thromboembolic, inflammatory mechanisms are implicated. ALI is a medical emergency that puts both limb and the patient\u2019s life at risk. In patients over age 80 undergoing surgery, mortality remains high reaching approximately 40% as well as amputation approximately 11%. The purpose of this paper is to summarize the scientific evidence on the possibilities of primary and secondary prevention of ALI and to raise awareness among doctors involved in the management of ALI, in particular by describing the central role of the general practitioner.<\/jats:p>","DOI":"10.3390\/jcm12113652","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T02:00:55Z","timestamp":1684980055000},"page":"3652","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Focus on the Prevention of Acute Limb Ischemia: Centrality of the General Practitioner from the Point of View of the Internist"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3349-1443","authenticated-orcid":false,"given":"Iolanda","family":"Enea","sequence":"first","affiliation":[{"name":"Emergency Department, S. Anna and S. Sebastiano Hospital, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5764-0082","authenticated-orcid":false,"given":"Eugenio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Division of Vascular Surgery, Department of Cardiovascular Science, S. Anna and S. Sebastiano Hospital, Campania, 81100 Caserta, Italy"},{"name":"Department of General and Specialist Surgery Paride Stefanini, Faculty of Pharmacy and Medicine, Sapienza University of Rome, 00161 Rome, Italy"},{"name":"Medicine and Surgery School of Medicine, Saint Camillus International University of Health Science, 00131 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1093\/eurheartj\/ehx095","article-title":"2017 ESC guidelines on the diagnosis and treatment of Periphera Arterial Diseases in collaboration with the European Society for Vascular Surgery (ESVS)","volume":"39","author":"Aboyans","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"75e","DOI":"10.1016\/j.avsg.2017.07.034","article-title":"Analysis of patients undergoing major extremity amputation in the vascular quality initiative","volume":"46","author":"Gabel","year":"2018","journal-title":"Ann. Vasc. Surg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1161\/CIRCULATIONAHA.115.016424","article-title":"Population based study of incidence, risk factors, outcome, and prognosis of ischemic peripheral arterial events: Implications for prevention","volume":"132","author":"Howard","year":"2015","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejvs.2019.09.006","article-title":"European Society for Vascular Surgery (ESVS) 2020 Clinical practice Guidelines","volume":"59","author":"Earnshaw","year":"2020","journal-title":"Eur. J. Endovasc. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1020","DOI":"10.1016\/S2214-109X(19)30255-4","article-title":"Global, regional, and national prevalence and risk factors for peripheral artery disease in 2015: An updated systematic review and analysis","volume":"7","author":"Song","year":"2019","journal-title":"Lancet Global Health"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-0040-1713769","article-title":"Acute Lower Limb Ischemia\u2014Etiology, Pathology, and Management","volume":"29","author":"Natarajan","year":"2020","journal-title":"Int. J. Angiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCULATIONAHA.119.039773","article-title":"Acute Limb Ischemia in Peripheral Artery Disease. Insight from EUCLID","volume":"140","author":"Hess","year":"2019","journal-title":"Circulation"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"115e21","DOI":"10.1161\/CIRCULATIONAHA.113.003543","article-title":"Twenty-year analysis of trends in the incidence and in-hospital mortality for lower-extremity arterial thromboembolism","volume":"128","author":"Korabathina","year":"2013","journal-title":"Circulation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jvs.2014.03.244","article-title":"Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population","volume":"60","author":"Baril","year":"2014","journal-title":"J. Vasc. Surg."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","article-title":"Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004","volume":"124","author":"Pande","year":"2011","journal-title":"Circulation"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.avsg.2021.10.068","article-title":"Rates of intervention for claudication versus chronic limb threatening ischemia in Canada and United States","volume":"82","author":"Li","year":"2022","journal-title":"Ann. Vasc. Surg."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa2207899","article-title":"for the BEST-CLI investigators. Surgery or Endovascular Therapy for Chronic Limb-Threatening Ischemia","volume":"387","author":"Farber","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMe2214046","article-title":"Surgical Revascularization\u2014Best for Limb Ischemia?","volume":"387","author":"Golledge","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0140-6736(05)67704-5","article-title":"Bypass versus angioplasty in severe ischemia of the leg (BASIL): Multicentre, randomized controlled trial","volume":"366","author":"Adam","year":"2005","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1055\/s-0038-1676094","article-title":"Multidisciplinary approach to PAD: Who\u2019s on your team?","volume":"35","author":"Dhand","year":"2018","journal-title":"Semin. Intervent. Radiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1161\/CIRCULATIONAHA.107.725101","article-title":"for the Peripheral Arterial Disease Coalition. Gaps in public knowledge of peripheral arterial disease: The first national PAD awareness survey","volume":"116","author":"Hirsch","year":"2007","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2017.02.064","article-title":"Underuse of prevention and life style counseling in patients with peripheral artery disease","volume":"69","author":"Berger","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Oude Wesselink, S.F., Lingsma, H.F., Robben, P.B., and Mackenbach, J.P. (2015). Guideline adherence and health outcome in diabetes mellitus type 2 patients: A cross sectional study. BMC Health Serv. Res., 15.","DOI":"10.1186\/s12913-014-0669-z"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1001\/jama.286.11.1317","article-title":"Peripheral Arterial Disease detection, awareness, and treatment in primary care","volume":"286","author":"Hirsch","year":"2001","journal-title":"JAMA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: A systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/1358863X13475836","article-title":"Gender related variation in the clinical presentation and outcomes of critical limb ischemia","volume":"18","author":"McCoach","year":"2013","journal-title":"Vasc. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jvs.2006.10.032","article-title":"Intrinsic contribution of gender and ethnicity to normal ankle brachial index values: The Multi-Ethnic Study of Atherosclerosis (MESA)","volume":"45","author":"Abayans","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.atherosclerosis.2011.01.003","article-title":"The role of nicotine in the pathogenesis of atherosclerosis","volume":"215","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacc.2019.05.049","article-title":"Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases","volume":"74","author":"Ding","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e010674","DOI":"10.1161\/JAHA.118.010674","article-title":"Cigarette smoking and sub clinical peripheral arterial disease in Blacks of the Jackson Heart Study","volume":"8","author":"Clark","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/j.jvs.2014.08.064","article-title":"Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease","volume":"60","author":"Armstrong","year":"2014","journal-title":"J. Vasc. Surg."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/j.jacc.2010.07.031","article-title":"Effectiveness of a smoking cessation program for peripheral artery disease patients: A randomized controlled trial","volume":"56","author":"Henrikus","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e937","DOI":"10.1161\/CIR.0000000000000669","article-title":"New and emerging tobacco products and the nicotine endgame: The role of robust regulation and comprehensive tobacco control and prevention: A presidential advisory from the American Heart Association","volume":"139","author":"Bhatnagar","year":"2019","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.avsg.2016.06.005","article-title":"VAPOR investigators. Impact and duration of brief surgeon-delivered smoking cessation advice on attitudes regarding nicotine dependence and tobacco harms for patients with peripheral arterial disease","volume":"38","author":"Newhall","year":"2017","journal-title":"Ann. Vasc. Surg."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e013534","DOI":"10.1161\/JAHA.119.013534","article-title":"Physical Activity and Subsequent Risk of Hospitalization with Peripheral Artery Disease and Critical Limb Ischemia in the ARIC study","volume":"8","author":"Lu","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_31","first-page":"CD000990","article-title":"Exercise for intermittent claudication","volume":"12","author":"Lane","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_32","first-page":"452","article-title":"Resistance training as a treatment for older persons with peripheral artery disease: A systematic review and meta-analysis","volume":"54","author":"Parmenter","year":"2020","journal-title":"Br. J. Sports Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.freeradbiomed.2010.06.033","article-title":"Plasma nitrite flux predicts exercise performance in peripheral arterial disease after 3 months of exercise training","volume":"49","author":"Allen","year":"2010","journal-title":"Free Radic. Biol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1161\/CIRCRESAHA.121.318242","article-title":"Walking exercise therapy effects on lower extremity skeletal muscle in peripheral artery disease","volume":"128","author":"McDermott","year":"2021","journal-title":"Circ. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1161\/CIRCRESAHA.118.313131","article-title":"Beet the best? Dietary inorganic Nitrate to augment Exercise Training in Lower Extremity Peripheral Artery Disease with Intermittent Claudication","volume":"123","author":"Woessner","year":"2018","journal-title":"Circ. Res."},{"key":"ref_36","first-page":"e700","article-title":"Implementation of supervised exercise therapy for patients with symptomatic peripheral artery disease: A science advisory from the American Heart Association","volume":"140","author":"McDermott","year":"2019","journal-title":"Circulation"},{"key":"ref_37","first-page":"e10","article-title":"Optimal exercise programs for patients with peripheral artery disease: A scientific statement from the American Heart Association","volume":"139","author":"McDermott","year":"2019","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamacardio.2022.5437","article-title":"Effect of brief counseling by allied health professionals on step count of people with peripheral artery disease: A randomized clinical trial","volume":"8","author":"Golledge","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1001\/jamacardio.2022.5443","article-title":"Walking Exercise for Peripheral Artery Disease","volume":"8","author":"McDermott","year":"2023","journal-title":"JAMA Cardiol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvx086","article-title":"New insight into the role of adipose tissue in thrombosis","volume":"113","author":"Vilahur","year":"2017","journal-title":"Cardiovasc. Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1160\/TH13-01-0075","article-title":"Thrombosis in central obesity and metabolic syndrome: Mechanisms and epidemiology","volume":"110","author":"Morange","year":"2013","journal-title":"Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ejvs.2006.10.006","article-title":"Obesity and thrombosis","volume":"33","author":"Darvall","year":"2007","journal-title":"Eur. J. Vasc. Endovasc. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e008644","DOI":"10.1161\/JAHA.118.008644","article-title":"Associations of Obesity with Incident Hospitalization Related to Peripheral Artery Disease and Critical Limb Ischemia in the ARIC Study","volume":"7","author":"HicKs","year":"2018","journal-title":"J. Am. Heart Assoc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/CIRCRESAHA.116.303849","article-title":"Epidemiology of peripheral artery disease","volume":"116","author":"Criqui","year":"2015","journal-title":"Circ. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2019.10.017","article-title":"Body mass index and peripheral artery disease","volume":"292","author":"Heffron","year":"2020","journal-title":"Atherosclerosis"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","article-title":"2020 ESC Guidelines for diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio Thoracic Surgery (EACTS): The Task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology developed with special contribution of the European heart Rhythm Association (EHRA) of the ESC","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1097\/HJH.0000000000000652","article-title":"Increased arterial stiffness is an independent predictor of atrial fibrillation in hypertensive patients","volume":"33","author":"Cremer","year":"2015","journal-title":"J. Hypertension"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1136\/heartjnl-2015-307438","article-title":"Association between diastolic dysfunction and future atrial fibrillation in the Troms Study from 1994 to 2010","volume":"101","author":"Tiwari","year":"2015","journal-title":"Heart"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Manapurathe, T.D., Krishna, S.M., Dewdney, B., Moxon, J.V., Biros, E., and Golledge, J. (2017). Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: A meta-analysis of randomized controlled trials. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0178713"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/HYPERTENSIONAHA.109.142240","article-title":"Outcomes among hypertensive patients with concomitant, peripheral and coronary artery disease: Findings from the INternational VErapamil-SR\/Trandolapril STudy","volume":"55","author":"Bavry","year":"2010","journal-title":"Hypertension"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e006512","DOI":"10.1161\/CIRCOUTCOMES.120.006512","article-title":"Association of Hyopertension and Arterial Blood Pressure on limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. The EUCLID Trial","volume":"13","author":"Fudim","year":"2020","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.amjmed.2003.09.038","article-title":"Effect of type 2 diabetes and its duration on the risk of peripheral arterial disease among men","volume":"116","author":"Merchant","year":"2004","journal-title":"Am. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.atherosclerosis.2018.04.042","article-title":"Traditional and nontraditional glycemic markers and risk of peripheral artery disease: The atherosclerosis risk in communities (ARIC) study","volume":"274","author":"Ding","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e3242","DOI":"10.1002\/dmrr.3242","article-title":"The patient presenting with chronic limb-threatening ischaemia. Does diabetes influence presentation, limb outcomes and survival?","volume":"36","author":"Fitridge","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_55","unstructured":"International Diabetes Federation (2023, March 31). Prevalence of Diabetes in Adults, Singapore. Available online: https:\/\/idf.org\/our-network\/regions-members\/western-pacific\/members\/113-singapore.html."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12933-021-01441-0","article-title":"Diabetes and other vascular risk factors in association with the risk of lower extremity amputation in chronic limb threatening ischemia: A prospective cohort study","volume":"21","author":"Ying","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1161\/CIRCRESAHA.116.306923","article-title":"Molecular and cellular mechanisms of cardiovascular disorders in diabetes","volume":"118","author":"Shah","year":"2016","journal-title":"Circ. Res"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2796.2007.01824.x","article-title":"Diabetes mellitus as a prothrombotic condition","volume":"262","author":"Grant","year":"2007","journal-title":"J. Intern. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1016\/j.jacc.2018.09.078","article-title":"Cardiovascular and Limb Outcomes in Patients with Diabetes and Peripheral Artery Disease. The EUCLID Trial","volume":"72","author":"Blomster","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e3276","DOI":"10.1002\/dmrr.3276","article-title":"Guidelines on diagnosis, prognosis, and management of peripheral artery disease with foot ulcers and diabetes (IWGDF 2019)","volume":"36","author":"Hinchliffe","year":"2020","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"De Nicola, L., Provenzano, M., Chiodini, P., Borrelli, S., Garofalo, C., Pacilio, M., Liberti, M.E., Sagliocca, A., Conte, G., and Minutolo, R. (2015). Independent role of underlying kidney disease on renal prognosis of patients with chronic kidney disease under nephrology care. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0127071"},{"key":"ref_62","first-page":"74","article-title":"Role of proteinuria in clinical research: For each old-answer, a new key-question","volume":"111","author":"Provenzano","year":"2020","journal-title":"Recent Prog. Med."},{"key":"ref_63","first-page":"e726","article-title":"Guideline on the management of patients with lower extremity peripheral artery disease: A report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"135","author":"Gornik","year":"2017","journal-title":"Circulation"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1681\/ASN.2016050562","article-title":"Global cardiovascular and renal outcomes of reduced GFR","volume":"28","author":"Thomas","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_65","first-page":"138","article-title":"Reclassification of chronic kidney disease patients for end-stage renal disease risk by proteinuria indexed to estimated glomerular filtration rate: Multicentre prospective study in nephrology clinics","volume":"35","author":"Provenzano","year":"2020","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","article-title":"Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: A collaborative meta-analysis of individual participant data","volume":"3","author":"Matsushita","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1161\/01.CIR.0000137913.26087.F0","article-title":"Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National health and nutrition examination survey, 1999\u20132000","volume":"110","author":"Selvin","year":"2004","journal-title":"Circulation"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fcell.2019.00314","article-title":"Unraveling cardiovascular risk in renal patients: A new take on old tale","volume":"3","author":"Provenzano","year":"2019","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"f5680","DOI":"10.1136\/bmj.f5680","article-title":"Blood Pressure Lowering Treatment Trialists\u2019 Collaboration. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: Meta-analysis of randomized controlled trials","volume":"347","author":"Ninomiya","year":"2013","journal-title":"BMJ"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1053\/j.ackd.2007.04.005","article-title":"Novel and traditional cardiovascular risk factors for peripheral arterial disease in incident-dialysis patients","volume":"14","author":"Jaar","year":"2007","journal-title":"Adv. Chronic Kidney Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJMcp1709326","article-title":"Chronic limb-threatening ischemia","volume":"379","author":"Farber","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jvs.2007.01.025","article-title":"Refinement of survival prediction in patients undergoing lower extremity bypass surgery: Stratification by chronic kidney disease classification","volume":"45","author":"Owens","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: Insights from the FOURIER Trial (Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Patel, H.P., Decter, D., Thaccar, S., Anantha-Narayanan, M., Kumar, A., Sheth, A.R., Zahid, S., Platel, B.A., Patel, T., and Devani, H. (2022). Impact of Chronic Kidney Disease on In-Hospital Outcomes of Hospitalizations With Acute Limb Ischemia Undergoing Endovascular Therapy. J. Endovasc. Ther.","DOI":"10.1177\/15266028221134887"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.kisu.2017.07.005","article-title":"Strategies to improve monitoring disease progression, assessing cardiovascular risk, and defining prognostic biomarkers in chronic kidney disease","volume":"7","author":"Pena","year":"2017","journal-title":"Kidney Int. Suppl."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.2147\/IJGM.S322417","article-title":"The Impact of Chronic Kidney Disease on Peripheral Artery Disease and Peripheral Revascularization","volume":"14","author":"Serra","year":"2021","journal-title":"Int. J. General Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: A triumph of simplicity","volume":"27","author":"Boren","year":"2016","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur. Heart J."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration, Baigent, C., Blackwell, L., Emberson, J., Holland, L.E., Reith, C., Bhala, N., Peto, R., Barnes, E.H., and Keech, A. (2010). Efficacy and safety of more intendsive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet, 376, 1670\u20131681.","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jacc.2019.04.047","article-title":"Trajectories of Non-HDL Cholesterol Across Midlife: Implications for Cardiovascular Prevention","volume":"74","author":"Pencina","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"SCORE2 OP Working Group and ESC Cardiovascular Risk Collaboration (2021). SCORE2-op risk prediction algorithms: Estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur. Heart J., 42, 2455\u20132467.","DOI":"10.1093\/eurheartj\/ehab312"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e2245720","DOI":"10.1001\/jamanetworkopen.2022.45720","article-title":"Association of Lipoprotein (a) Levels with Incidence of Major Adverse Limb Events","volume":"5","author":"Guedon","year":"2022","journal-title":"JAMA Network Open"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jacc.2018.06.046","article-title":"Impact of lipids on cardiovascular health: JACC Health Promotion Series","volume":"72","author":"Ference","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"773214","DOI":"10.3389\/fcvm.2021.773214","article-title":"Antithrombotic treatment in lower extremity peripheral arterial disease","volume":"8","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","article-title":"Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"264","author":"Pastori","year":"2018","journal-title":"Int. J. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0741-5214(97)70045-4","article-title":"Recommended standards for report dealing with lower extremity ischemia: Revised version","volume":"26","author":"Rutherford","year":"1997","journal-title":"J. Vasc. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1016\/S0140-6736(17)32250-X","article-title":"Population screening and intervention for vascular disease in Danish men (VIVA): A randomized controlled trial","volume":"390","author":"Lindholt","year":"2017","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jvs.2015.03.043","article-title":"The Society for Vascular Surgery\u2019s objective performance goals for lower extremity revascularization are not generalizable to many open surgical bypass patients encountered in contemporary surgical practice","volume":"62","author":"Saraidaridis","year":"2015","journal-title":"J. Vasc. Surg."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e000697","DOI":"10.1161\/JAHA.113.000697","article-title":"Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease","volume":"3","author":"Armstrong","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_90","first-page":"S1","article-title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","volume":"58","author":"Conte","year":"2019","journal-title":"J. Vasc. Surg."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1177\/1358863X20987612","article-title":"Medical therapy for cardiovascular and limb-related risk reduction in critical limb ischemia","volume":"26","author":"Giannopulos","year":"2021","journal-title":"Vasc. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC)","volume":"34","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symprtomatic Peripheral Artery Disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with Peripheral Artery Disease. The COMPASS Trial","volume":"71","author":"Anand","year":"2018","journal-title":"JACC"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Heart Protection Study Collaborative Group (2007). Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J. Vasc. Surg., 45, 645\u2013654.","DOI":"10.1016\/j.jvs.2006.12.054"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","article-title":"Statins: Mechanism of action and effects","volume":"5","author":"Stancu","year":"2001","journal-title":"J. Cell Mol. Med."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: Randomized controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"BMJ"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"FIELD Study Investigators (2005). Effects of long-term fenifibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomized controlled trial. Lancet, 366, 1849\u20131861.","DOI":"10.1016\/S0140-6736(05)67667-2"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1016\/S0140-6736(09)60698-X","article-title":"FIELD investigators. Effect of Fenofibrate on amputation events in people with type 2 diabete mellitus (FIELD study): A prespecified analysis of a randomized controlled trial","volume":"373","author":"Rajamani","year":"2009","journal-title":"Lancet"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"ACCORD study group. Effect of combination lipid therapy in type2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/clp.10.84","article-title":"The ACCORD-Lipid study: Implication for treatment of dyslipidemia in type 2 diabetes mellitus","volume":"6","author":"Elam","year":"2011","journal-title":"Clin. Lipidol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11883-020-00846-8","article-title":"Triglycerides and ASCVD risk reduction: Recent insights and future directions","volume":"22","author":"Hussain","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMe2213208","article-title":"The fibrate story\u2014A tepid end to a PROMINENT Drug","volume":"387","author":"Virani","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular risk: The STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1001\/jamacardio.2021.1157","article-title":"Association between Achieved \u03c9-3 Fatty Acid levels and Major Adverse Cardiovascular outcomes in patients with high cardiovascular risk: A secondary analysis of the STRENGTH trial","volume":"6","author":"Nisse","year":"2021","journal-title":"JAMA Cardiol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1093\/ehjcvp\/pvab010","article-title":"Has the \u201cstrength\u201d of fish oil therapy been \u201creduced?\u201d: Reconciling the results of REDUCE-IT and STRENGTH","volume":"7","author":"Virani","year":"2021","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1161\/01.CIR.83.2.438","article-title":"Effects of colestipol-niacin therapy on human femoral atherosclerosis","volume":"83","author":"Blankenhorn","year":"1991","journal-title":"Circulation"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.atherosclerosis.2011.04.005","article-title":"The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline","volume":"218","author":"West","year":"2011","journal-title":"Atherosclerosis"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended release of niacin or ezetimibe and carotid intima media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jacc.2019.03.013","article-title":"Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES trial","volume":"74","author":"Jukema","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMe2301490","article-title":"Benefits of bempedoic acid-Clearer now","volume":"388","author":"Alexander","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJMe2300793","article-title":"Bempedoic Acid and the prevention of cardiovascular disease","volume":"388","author":"Keaney","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_119","first-page":"104413","article-title":"A new Dawn for management of dyslipidemias: The era of RNA based therapies","volume":"150","author":"Macchi","year":"2019","journal-title":"Pharmac. Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/eurheartj\/ehac594","article-title":"Inclisiran and cardiovascular events: A patient-level analysis of phase III trials","volume":"44","author":"Ray","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S2213-8587(22)00353-9","article-title":"Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION 3): Results from the 4-year open-label extension of the ORION-1 trial","volume":"11","author":"Ray","year":"2023","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"CAPRIE Steering Committee (1996). A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329\u20131339.","DOI":"10.1016\/S0140-6736(96)09457-3"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(17)32409-1","article-title":"Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: An international, randomised, double-blind, placebo-controlled trial","volume":"391","author":"Anand","year":"2018","journal-title":"Lancet"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa2000052","article-title":"Rivaroxaban in peripheral artery disease after revascularization","volume":"382","author":"Bonaca","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"Yusuf","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/1358863X15574321","article-title":"Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major advers cardiovascular events among patients with critical limb-ischemia","volume":"20","author":"Armstrong","year":"2015","journal-title":"Vasc. Med."},{"key":"ref_129","first-page":"CD005508","article-title":"Beta blockers for peripheral arterial disease","volume":"9","author":"Paravastu","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_130","first-page":"148","article-title":"Beta-blockers in patients with intermittent claudication and arterial hypertension: Results from the nebivolol or metoprolol in arterial occlusive disease trial","volume":"5","author":"Weisser","year":"2011","journal-title":"Hypertension"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre diabetes and cardiovascular diseases developed in collaboration with EASD: The Task Force for diabetes, Pre-diabetes and cardiovascular diseases of the European Society of Cardiology and the European Association for the study of diabetes (EASD)","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCULATIONAHA.117.032031","article-title":"Cardiovascular outcomes and safety of empagliflozin in patients with type 2 diabetes mellitus and peripheral artery disease: A subanalysis of EMPAREG OUTCOME","volume":"137","author":"Verma","year":"2018","journal-title":"Circulation"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1161\/CIRCULATIONAHA.119.044775","article-title":"Dapagliflozin and cardiac, kidney, and limb outcomes in patients with and without peripheral artery disease in DECLARE-TIMI 58","volume":"142","author":"Bonaca","year":"2020","journal-title":"Circulation"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1111\/dom.14671","article-title":"Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trial","volume":"24","author":"Barraclough","year":"2022","journal-title":"Diabetes Obes. Metab."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.atherosclerosis.2006.01.022","article-title":"Activation of endothelial nitric oxide synthase by cilostazol via a cAMP\/protein kinase A\u2014And phosphatidylinositol 3-kinase\/Akt-dependent mechanism","volume":"189","author":"Hashimoto","year":"2006","journal-title":"Atherosclerosis"},{"key":"ref_138","first-page":"777","article-title":"Cilostazol: A review of basic mechanisms and clinical uses. Cardiovasc","volume":"36","author":"Kherallah","year":"2021","journal-title":"Drugs Ther."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jvs.2020.08.125","article-title":"Literature review and meta-analysis of the efficacy of cilostazol on limb salvage rates after infrainguinal endovascular and open revascularization","volume":"73","author":"Desai","year":"2021","journal-title":"J. Vasc. Surg."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e019672","DOI":"10.1161\/JAHA.120.019672","article-title":"Network meta-analysis comparing the outcomes of treatments for intermittent claudication tested in randomized controlled trials","volume":"10","author":"Thanigaimani","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/pds.4167","article-title":"Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany","volume":"26","author":"Castellsague","year":"2017","journal-title":"Pharmacoepidemiol. Drug. Saf."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/eurheartj\/ehu071","article-title":"Non-coronary atherosclerosis","volume":"35","author":"Gallino","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"777016","DOI":"10.3389\/fcvm.2021.777016","article-title":"Statins and Peripheral Arterial Disease: A Narrative Review","volume":"8","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"100371","DOI":"10.1016\/j.ajpc.2022.100371","article-title":"There is urgent need to treat atherosclerotic cardiovascular disease risk earlier, more intensively, and with greater precision: A review of current practice and recommendations for improved effectiveness","volume":"12","author":"Makover","year":"2022","journal-title":"Am. J. Prevent. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3652\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:41:26Z","timestamp":1760125286000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/11\/3652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":144,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["jcm12113652"],"URL":"https:\/\/doi.org\/10.3390\/jcm12113652","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,24]]}}}